サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1737375

乾癬性関節炎治療の世界市場

Psoriatic Arthritis Treatment

出版日
ページ情報
英文 452 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.00円
乾癬性関節炎治療の世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 452 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

乾癬性関節炎治療の世界市場は2030年までに163億米ドルに到達

2024年に108億米ドルと推定される乾癬性関節炎治療の世界市場は、2024～2030年の分析期間にCAGR 7.1％で成長し、2030年には163億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである生物製剤は、CAGR6.3%を記録し、分析期間終了時には95億米ドルに達すると予想されます。非生物製剤セグメントの成長率は、分析期間中CAGR 8.1％と推定されます。

米国市場は29億米ドルと推定、中国はCAGR 11.0％で成長予測

米国の乾癬性関節炎治療市場は、2024年に29億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに34億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.6%と6.9%と予測されています。欧州では、ドイツがCAGR 4.7%で成長すると予測されています。

世界の「乾癬性関節炎治療」市場- 個別化された自己免疫ケアの時代は到来するか？

疾患意識の高まりが早期診断・早期治療を促進？

乾癬に関連する慢性炎症性疾患である乾癬性関節炎（PsA）は、社会的・臨床的認知度の向上により認知度が高まっています。以前は過小診断や誤診であったPsAが、現在では早期に発見されるようになり、タイムリーな治療介入とより良い転帰につながっています。ヘルスケア機関、皮膚科クリニック、リウマチ学会による啓発キャンペーンの増加により、関節の不快感やこわばりを早期に報告するよう患者に呼びかけています。画像診断やバイオマーカー検査における技術革新は診断精度を高め、患者支援コミュニティは積極的に治療を求める行動を促しています。これらの要因により、疾患の進行やQOLを決定する重要な要素である早期段階での治療開始が促進されています。

生物学的製剤と標的療法は治療状況を一変させるか？

PsA治療市場は、生物学的製剤と低分子阻害剤の登場によって劇的な変化を遂げました。TNF阻害剤、IL-17阻害剤、IL-23阻害剤、JAK阻害剤が第一線の治療薬として登場し、より的を絞った免疫調節を行い、有効性の向上と全身的な副作用の軽減を実現しています。生物学的製剤の価格がより手頃になり、バイオシミラーが市場に参入するにつれて、さまざまな地域でアクセスが拡大しています。さらに、PDE4阻害剤のような経口療法は、注射可能な生物学的製剤を使用したくない、あるいは使用できない患者にとって、より便利な選択肢を提供しています。臨床ガイドラインは、関節の損傷を防ぐために生物学的製剤を早期に使用することを支持するようになっており、先進的な治療法に対する需要をさらに押し上げています。

患者中心の治療は治療のカスタマイズを促進するか？

乾癬性関節炎は患者によって症状が異なるため、個別化された治療戦略が重要となります。リウマチ診療では、患者と医療者が協力して、併存疾患、ライフスタイルの嗜好、治療目標に基づいて治療法を選択する共同意思決定が普及しています。デジタルヘルスツールは、症状、服薬アドヒアランス、薬物療法への反応を追跡し、ケアプランをリアルタイムで調整するのに役立っています。また、患者は潜在的な副作用、アクセスプログラム、代替治療法についての知識を深めています。個別化治療へのシフトとアクセス支援サービスの向上は、治療の満足度と持続性を高め、多様な治療提供への需要を強化しています。

乾癬性関節炎治療市場の成長はいくつかの要因によって牽引...

乾癬性関節炎治療市場の成長は、治療法の革新、より広範な診断、患者のエンゲージメントダイナミクスの変化など、いくつかの要因によって牽引されています。技術的には、新しい生物学的経路や経口剤の開発により、より高い有効性と特異性を持つ治療の選択肢が広がっています。最終用途の成長は、連携ケアや保険ナビゲーションを提供するリウマチクリニックや専門薬局で観察されます。消費者の動向は、デジタルヘルスツールの利用拡大や臨床試験への参加など、情報に基づいた積極的な疾患管理へとシフトしています。さらに、自己免疫疾患治療薬のパイプラインに対する製薬企業の投資の増加、新興国市場での有病率の上昇、償還制度の強化が、PsA治療薬の世界の拡大を後押ししています。

セグメント

薬剤クラス別（生物学的製剤、非生物学的製剤、併用療法）;製品タイプ別（処方薬、市販薬）;投与経路別（非経口薬、経口薬）;販売チャネル別（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の32社）

  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • Janssen Pharmaceuticals（Johnson & Johnson）
  • Merck & Co., Inc.
  • MoonLake Immunotherapeutics
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34265

Global Psoriatic Arthritis Treatment Market to Reach US$16.3 Billion by 2030

The global market for Psoriatic Arthritis Treatment estimated at US$10.8 Billion in the year 2024, is expected to reach US$16.3 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$9.5 Billion by the end of the analysis period. Growth in the Non-biologics segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 11.0% CAGR

The Psoriatic Arthritis Treatment market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global "Psoriatic Arthritis Treatment" Market - Is the Era of Personalized Autoimmune Care Here?

Is Rising Disease Awareness Catalyzing Early Diagnosis and Treatment?

Psoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, is gaining recognition due to rising public and clinical awareness. Previously underdiagnosed or misdiagnosed, PsA is now being identified earlier, leading to timely therapeutic intervention and better outcomes. Increased awareness campaigns by healthcare organizations, dermatology clinics, and rheumatology societies are encouraging patients to report early joint discomfort or stiffness. Innovations in imaging and biomarker testing are enhancing diagnostic accuracy, while patient support communities are driving proactive care-seeking behavior. These factors are boosting early-stage treatment initiation, a crucial determinant of disease progression and quality of life.

Are Biologic and Targeted Therapies Transforming the Treatment Landscape?

The PsA treatment market has undergone a dramatic shift with the advent of biologics and small molecule inhibitors. TNF inhibitors, IL-17 and IL-23 inhibitors, and JAK inhibitors have emerged as frontline therapies, offering more targeted immunomodulation with improved efficacy and reduced systemic side effects. As biologics become more affordable and biosimilars enter the market, access is expanding across different geographies. Additionally, oral therapies such as PDE4 inhibitors are providing more convenient options for patients unwilling or unable to use injectable biologics. Clinical guidelines are increasingly supporting early biologic use to prevent joint damage, further pushing demand for advanced therapies.

Is Patient-Centered Care Driving Treatment Customization?

Psoriatic arthritis manifests differently among patients, making personalized treatment strategies critical. Shared decision-making is gaining traction in rheumatology practices, with patients and providers working together to select therapies based on comorbidities, lifestyle preferences, and treatment goals. Digital health tools are helping track symptoms, adherence, and response to medication, enabling real-time adjustments to care plans. Patients are also more educated about potential side effects, access programs, and alternative treatment options. This shift toward individualized therapy and improved access support services is enhancing treatment satisfaction and persistence, reinforcing demand for diverse therapeutic offerings.

The Growth in the Psoriatic Arthritis Treatment Market Is Driven by Several Factors…

The growth in the psoriatic arthritis treatment market is driven by several factors including therapeutic innovation, broader diagnosis, and changing patient engagement dynamics. Technologically, the development of new biologic pathways and oral agents is expanding treatment options with higher efficacy and specificity. End-use growth is observed in rheumatology clinics and specialty pharmacies that provide coordinated care and insurance navigation. Consumer trends are shifting toward informed, proactive disease management with greater use of digital health tools and participation in clinical trials. Further, increasing pharmaceutical investments in autoimmune drug pipelines, rising prevalence in developed markets, and stronger reimbursement frameworks are reinforcing the expansion of PsA treatment offerings worldwide.

SCOPE OF STUDY:

The report analyzes the Psoriatic Arthritis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Biologics, Non-biologics, Combination Therapy); Product Type (Prescription & Over-the-Counter); Administration Route (Parenteral, Oral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Merck & Co., Inc.
  • MoonLake Immunotherapeutics
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Psoriatic Arthritis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Autoimmune and Inflammatory Disorders Spurs Therapy Demand
    • Biologic Drug Innovations Propel Market Growth Through Improved Patient Outcomes
    • Shift Toward Early Diagnosis and Intervention Strengthens Use of DMARDs and Biologics
    • Expansion of Specialty Clinics and Rheumatology Centers Increases Treatment Accessibility
    • Pipeline Advancements in Oral Small Molecule Drugs Generate Competitive Momentum
    • Patient Demand for Targeted Therapies with Fewer Side Effects Drives R&D Investment
    • Integration of Companion Diagnostics Enhances Personalized Treatment Approaches
    • Telehealth Growth Expands Access to Specialist Care and Prescription Services
    • Improved Patient Education and Disease Awareness Strengthens Adherence to Long-Term Therapies
    • Health Insurance Expansion and Reimbursement Support Promote Biologic Drug Uptake
    • Rise of Combination Therapies Creates New Revenue Streams for Pharma Players
    • Ongoing Clinical Trials Exploring Novel Mechanisms of Action Expand Treatment Options
    • Increased Physician Familiarity with New Drug Classes Accelerates Prescribing Behavior
    • Regulatory Approvals Across Emerging Markets Expand Access to Advanced Therapies
    • Partnerships Between Pharma Companies and Advocacy Groups Drive Patient Support Programs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Psoriatic Arthritis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Psoriatic Arthritis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Prescription & Over-the-Counter by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Prescription & Over-the-Counter by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Prescription & Over-the-Counter by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Psoriatic Arthritis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Spain 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Russia 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 158: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Russia Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Russia 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Europe Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 182: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 194: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Australia Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Australia 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 197: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Australia Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Australia 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 206: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: India Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: India 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 209: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: India Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: India 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 212: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 218: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: South Korea Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: South Korea 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 221: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: South Korea Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: South Korea 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 230: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 242: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Latin America Historic Review for Psoriatic Arthritis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 245: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Latin America Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 257: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Argentina Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Argentina 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 260: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Argentina Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Argentina 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 269: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Brazil Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Brazil 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 272: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Brazil Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Brazil 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 281: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Mexico Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Mexico 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 284: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Mexico Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Mexico 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 293: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Latin America Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Latin America Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 305: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 306: Middle East Historic Review for Psoriatic Arthritis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 308: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Middle East Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 320: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Iran Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Iran 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 323: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Iran Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Iran 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 332: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Israel Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Israel 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 335: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Israel Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Israel 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 344: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Saudi Arabia Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Saudi Arabia 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 347: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Saudi Arabia Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Saudi Arabia 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 356: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: UAE Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: UAE 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 359: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: UAE Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: UAE 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 368: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Rest of Middle East Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Rest of Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 371: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Rest of Middle East Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Rest of Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 380: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Africa Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Africa 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 383: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Africa Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Africa 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION